A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma
Study of Metronomic and Targeted Anti-Angiogenesis Therapy For Children with Medullobastoma (Brain Tumor)
Sponsor: Internal
Enrolling: Male and Female Patients
IRB Number: AAAS0823
U.S. Govt. ID: NCT01356290
Contact: Rebecca Zylber, CPNP: 212-305-7212 / rjv2107@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn more about the treatment of children and young adults patient with relapsed (has returned) and progressive medulloblastoma (brain tumor). This study is being done to find out if bevacizumab can be safely given in combination with five study drugs given by mouth, thalidomide, fenofibrate, celecoxib and alternating every three weeks of etoposide and cyclophosphamide. Researchers want to evaluate whether the frequent delivery of low doses of study drugs chemotherapy will work for your cancer, while reducing the toxicity associated with standard dose chemotherapy. The study drugs will be given for 12 months duration based on how well the participants will tolerate the study drugs and the response. Each treatment cycle is 21 days long. The study is composed of the following periods: Screening, Treatment and Follow-up.
This study is closed
Stergios Zacharoulis, MD
Do You Qualify?
Is your child 0-20 years of age at the time of the original diagnosis? Yes No
Has your child's medullobastoma (brain tumor) progressed or come back after treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Rebecca Zylber, CPNP